Company Overview - Glaukos Corporation (GKOS) is a leading ophthalmic medical technology and pharmaceutical company with a market capitalization of 7.65billion[2]−Thecompany′sshareshaverisen71.6377-379millionfrom370-376millionduetohighproductdemand[6]ProductPortfolioExpansion−TheiStentportfoliosignificantlyboostedGlaukos′glaucomafranchiserevenuesinthefirstninemonthsof2024[7]−ThelaunchofiDoseTRinthesecondquarterisalreadyenhancingrevenuegrowth,withapermanentJ−codeeffectivefromJuly1likelytoincreasepatientaccessanddrivefuturesales[7]−Glaukosisinvestinginitsproductpipeline,includingEpioxa,acornealcross−linkingtherapyexpectedtoundergoNDAsubmissionbytheendof2024[8]−Thecompanyispreparingforapivotalstudyonitsnext−generationiDosetherapy,iDoseTREX,whichissettobeginsoon[9]InternationalExpansion−Glaukossellsitsproductsthroughsubsidiariesin17countriesandindependentdistributorsinothermarkets[10]−Thecompany′sinternationalglaucomafranchisereportedrecordsalesof83.5 million in the first nine months of 2024, reflecting 17% year-over-year growth [10] Challenges - Glaukos depends on a limited number of third-party suppliers, including some sole suppliers, for components of the iStent, iStent inject models, and other pipeline products [11] - If these suppliers fail to provide sufficient quantities of components or drugs in a timely manner or on acceptable terms, Glaukos would need to seek alternative sources [12] Financial Estimates - The bottom-line estimate for GKOS is pegged at a loss of 1.90persharefor2024,whichnarrowed30centsinthepast60days[13]−TheZacksConsensusEstimatefor2024revenuesispinnedat378.7 million, indicating growth of 20.3% from the top line recorded in 2023 [13] Industry Comparison - Other top-ranked stocks in the broader medical space include Masimo (MASI), Accuray (ARAY), and AxoGen (AXGN) [14] - Masimo has an estimated growth rate of 11.8% for 2025 and has seen its shares rise 48.6% year to date [14] - Accuray has an estimated growth rate of 1200% for 2025 but has seen its shares lose 25.8% year to date [15] - AxoGen has an estimated earnings growth rate of 252% for 2025 and has seen its shares rise 111.4% year to date [16]
Glaukos(GKOS) ZACKS·2024-12-11 14:36